Increased stroke risk in atrial fibrillation patients with heart failure does ejection fraction matter?

Stroke

Volumn 46, Issue 3, 2015, Pages 608-609

  Kotecha, Dipak ^a   Banerjee, Amitava ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Editorials; Ejection fraction; Heart failure; Stroke

Indexed keywords

ADVERSE OUTCOME; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSIENT ISCHEMIC ATTACK; DIAGNOSIS; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; PATHOPHYSIOLOGY; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; FEMALE; HEART FAILURE; HUMANS; MALE; THROMBOEMBOLISM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84935507971     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.008421     Document Type: Short Survey

References (16)

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
2. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther. 2014;36:1135-1144. doi: 10.1016/j.clinthera.2014.07.015.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
4. Sandhu RK, Hohnloser SH, Pfeffer MA, Yuan F, Hart RG, Yusuf S, et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke. 2015;46:667-672. doi: 10.1161/STROKEAHA.114.007140.
5. Gurwitz JH, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA, et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med. 2013;126:393-400. doi: 10.1016/j.amjmed.2012.10.022.
6. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/eurheartj/ehs253.
7. Badheka AO, Rathod A, Kizilbash MA, Bhardwaj A, Ali O, Afonso L, et al. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol. 2011;108:1283-1288. doi: 10.1016/j. amjcard.2011.06.045.
8. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al; ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013;6:451-460. doi: 10.1161/CIRCHEARTFAILURE.112.000143.
9. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004. doi: 10.1016/j. jacc.2006.01.060.
10. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail. 2012;14:295-301. doi: 10.1093/eurjhf/hfs005.
11. Eapen ZJ, Greiner MA, Fonarow GC, Yuan Z, Mills RM, Hernandez AF, et al. Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J. 2014;167:369-375.e2. doi: 10.1016/j.ahj.2013.12.001.
12. Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J. 2005;150:701-706. doi: 10.1016/j.ahj.2004.12.014.
13. McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, et al; Cardiovascular Research Network PRESERVE Study. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013;2:e005694. doi: 10.1161/JAHA.112.005694.
14. Patel HC, Hayward C, di Mario C, Cowie MR, Lyon AR, Rosen SD. Heart failure with preserved ejection fraction: the impact of stricter definitions. Eur J Heart Fail. 2014;16:767-771. doi: 10.1002/ejhf.106.
15. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128:2192-2201. doi: 10.1161/CIRCULATIONAHA.112.000491.
16. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-2243. doi: 10.1016/S0140-6736 (14) 61373-8.